Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE OTCMKTS:BVNRY NASDAQ:IMVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$134.28$109.68$34.34▼$134.46$8.31B0.321.69 million shs920,041 shsBVNRYBavarian Nordic$8.81+0.6%$9.41$8.67▼$13.00$2.08B1.23,355 shs411 shsIMVTImmunovant$40.09+1.7%$36.14$14.32▼$41.23$8.13B0.76980,201 shs930,537 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%+0.10%+1.31%+57.29%+228.96%BVNRYBavarian Nordic+0.61%-4.78%-2.62%-8.48%-27.58%IMVTImmunovant+1.73%+0.43%+3.19%+48.54%+136.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$134.28$109.68$34.34▼$134.46$8.31B0.321.69 million shs920,041 shsBVNRYBavarian Nordic$8.81+0.6%$9.41$8.67▼$13.00$2.08B1.23,355 shs411 shsIMVTImmunovant$40.09+1.7%$36.14$14.32▼$41.23$8.13B0.76980,201 shs930,537 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics0.00%+0.10%+1.31%+57.29%+228.96%BVNRYBavarian Nordic+0.61%-4.78%-2.62%-8.48%-27.58%IMVTImmunovant+1.73%+0.43%+3.19%+48.54%+136.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.24Hold$121.25-9.70% DownsideBVNRYBavarian Nordic 0.00N/AN/AN/AIMVTImmunovant 2.50Moderate Buy$42.115.04% UpsideCurrent Analyst Ratings BreakdownLatest BVNRY, APGE, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026APGEApogee Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026IMVTImmunovant Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/30/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$57.00 ➝ $61.006/24/2026APGEApogee Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$110.00 ➝ $135.006/24/2026APGEApogee Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold$110.00 ➝ $135.006/24/2026APGEApogee Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$133.00 ➝ $135.006/23/2026APGEApogee Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/23/2026APGEApogee Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/23/2026APGEApogee Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$100.00 ➝ $135.116/23/2026APGEApogee Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$125.00 ➝ $135.006/22/2026APGEApogee Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$116.00 ➝ $135.00(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.23 per shareN/ABVNRYBavarian Nordic$945.43M2.22$1.35 per share6.51$8.20 per share1.07IMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$255.84M-$4.33N/AN/AN/AN/A-32.64%-31.25%8/10/2026 (Estimated)BVNRYBavarian Nordic$208.23M$0.7611.60N/AN/A19.74%9.32%8.14%N/AIMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/6/2026 (Estimated)Latest BVNRY, APGE, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026APGEApogee Therapeutics-$1.10N/AN/AN/A$10.00 millionN/A8/6/2026Q1 2027IMVTImmunovant-$0.66N/AN/AN/AN/AN/A5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/13/2026Q1 2026BVNRYBavarian NordicN/A$0.01N/A$0.01N/A$165.70 million5/11/2026Q1 2026APGEApogee Therapeutics-$1.0658-$1.06+$0.0058-$1.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ABVNRYBavarian NordicN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A32.5932.59BVNRYBavarian NordicN/A6.473.58IMVTImmunovantN/A9.099.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%BVNRYBavarian NordicN/AIMVTImmunovant47.08%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics24.30%BVNRYBavarian NordicN/AIMVTImmunovant1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9161.88 million46.84 millionOptionableBVNRYBavarian Nordic1,692237.71 millionN/ANot OptionableIMVTImmunovant120206.40 million202.48 millionOptionableBVNRY, APGE, and IMVT HeadlinesRecent News About These CompaniesImmunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative BuyJuly 27 at 12:00 AM | seekingalpha.comAffinity Asset Advisors LLC Sells 100,000 Shares of Immunovant, Inc. $IMVTJuly 25 at 3:12 AM | marketbeat.comImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026July 24, 2026 | finance.yahoo.comImmunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Hold" from BrokeragesJuly 22, 2026 | americanbankingnews.comKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmJuly 20, 2026 | globenewswire.comJennison Associates LLC Acquires 2,496,241 Shares of Immunovant, Inc. $IMVTJuly 20, 2026 | marketbeat.comImmunovant, Inc. (IMVT) Stock Price, News, Quote & History - Yahoo FinanceJuly 19, 2026 | finance.yahoo.comImmunovant, Inc. (NASDAQ:IMVT) Receives Average Rating of "Hold" from BrokeragesJuly 17, 2026 | marketbeat.comTuyl Christopher Van Sells 1,206 Shares of Immunovant (NASDAQ:IMVT) StockJuly 11, 2026 | insidertrades.comInsider Selling: Immunovant (NASDAQ:IMVT) Insider Sells $47,697.30 in StockJuly 10, 2026 | marketbeat.comImmunovant (NASDAQ:IMVT) COO Sells $80,523.80 in StockJuly 10, 2026 | marketbeat.comImmunovant (NASDAQ:IMVT) CTO Jay Stout Sells 3,487 Shares of StockJuly 10, 2026 | marketbeat.comImmunovant Rides Brepocitinib Momentum Into 2026July 7, 2026 | theglobeandmail.comImmunovant (NASDAQ:IMVT) CEO Sells 3,092 SharesJuly 7, 2026 | insidertrades.comPictet Asset Management Holding SA Has $11.73 Million Stock Position in Immunovant, Inc. $IMVTJuly 3, 2026 | marketbeat.comImmunovant (NASDAQ:IMVT) Director Atul Pande Sells 1,500 SharesJune 27, 2026 | insidertrades.comS&P 500 Futures Drop in Premarket Trading; ON Semiconductor, DaVita LagJune 26, 2026 | barrons.comImmunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?June 19, 2026 | zacks.comImmunovant Stock Gains 12.4% in a Month: What's Driving It?June 12, 2026 | zacks.comH.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial DataJune 3, 2026 | finance.yahoo.comAnalysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Immunovant (IMVT)May 30, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBVNRY, APGE, and IMVT Company DescriptionsApogee Therapeutics NASDAQ:APGE$134.28 0.00 (0.00%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$134.28 0.00 (0.00%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Bavarian Nordic OTCMKTS:BVNRY$8.81 +0.05 (+0.61%) As of 07/27/2026 11:42 AM EasternBavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.Immunovant NASDAQ:IMVT$40.09 +0.68 (+1.73%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$40.12 +0.03 (+0.07%) As of 04:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now AMD’s AI Bubble Could Burst Into Explosive Upside Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
